| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tatjana Prokšelj, Aleš Jerin, Dorotea Muck-Seler, Aleš Kogo. Decreased platelet serotonin concentration in Alzheimer's disease with involuntary emotional expression disorder. Neuroscience letters. vol 578. 2015-04-13. PMID:24970754. |
decreased platelet serotonin concentration in alzheimer's disease with involuntary emotional expression disorder. |
2015-04-13 |
2023-08-13 |
Not clear |
| Enrica Olivola, Mariangela Pierantozzi, Paola Imbriani, Claudio Liguori, Mario Stampanoni Bassi, Marco Conti, Vincenza D'Angelo, Nicola Biagio Mercuri, Alessandro Stefan. Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart. PloS one. vol 9. issue 7. 2015-03-30. PMID:25036938. |
the pd patient group showed a significantly reduced csf level of both 5-ht and 5-hiaa compared to either age-matched control subjects (n = 18), or alzheimer's disease patients (n = 20). |
2015-03-30 |
2023-08-13 |
human |
| Yvette I Sheline, Tim West, Kevin Yarasheski, Robert Swarm, Mateusz S Jasielec, Jonathan R Fisher, Whitney D Ficker, Ping Yan, Chengjie Xiong, Christine Frederiksen, Monica V Grzelak, Robert Chott, Randall J Bateman, John C Morris, Mark A Mintun, Jin-Moo Lee, John R Cirrit. An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Science translational medicine. vol 6. issue 236. 2014-12-29. PMID:24828079. |
serotonin signaling suppresses generation of amyloid-β (aβ) in vitro and in animal models of alzheimer's disease (ad). |
2014-12-29 |
2023-08-13 |
mouse |
| Bellinda Benhamú, Mar Martín-Fontecha, Henar Vázquez-Villa, Leonardo Pardo, María L López-Rodrígue. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease. Journal of medicinal chemistry. vol 57. issue 17. 2014-12-03. PMID:24850589. |
serotonin 5-ht6 receptor antagonists for the treatment of cognitive deficiency in alzheimer's disease. |
2014-12-03 |
2023-08-13 |
Not clear |
| Claus-Jürgen Scholz, Susanne Jungwirth, Walter Danielczyk, Heike Weber, Ildiko Wichart, Karl Heinz Tragl, Peter Fischer, Peter Riederer, Jürgen Deckert, Edna Grünblat. Investigation of association of serotonin transporter and monoamine oxidase-A genes with Alzheimer's disease and depression in the VITA study cohort: a 90-month longitudinal study. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 165B. issue 2. 2014-10-16. PMID:24443391. |
investigation of association of serotonin transporter and monoamine oxidase-a genes with alzheimer's disease and depression in the vita study cohort: a 90-month longitudinal study. |
2014-10-16 |
2023-08-12 |
human |
| Mohammad Seyedabadi, Gohar Fakhfouri, Vahid Ramezani, Shahram Ejtemaei Mehr, Reza Rahimia. The role of serotonin in memory: interactions with neurotransmitters and downstream signaling. Experimental brain research. vol 232. issue 3. 2014-10-14. PMID:24430027. |
in addition, there has been an alteration in the density of serotonergic receptors in aging and alzheimer's disease, and serotonin modulators are found to alter the process of amyloidogenesis and exert cognitive-enhancing properties. |
2014-10-14 |
2023-08-12 |
Not clear |
| Adriana Alexandre S Tavares, Fabien Caillé, Olivier Barret, Caroline Papin, Hsiaoju Lee, Thomas J Morley, Krista Fowles, Daniel Holden, John P Seibyl, David Alagille, Gilles D Tamagna. In vivo evaluation of 18F-MNI698: an 18F-labeled radiotracer for imaging of serotonin 4 receptors in brain. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. vol 55. issue 5. 2014-06-23. PMID:24686782. |
serotonin 4 receptors (5-hydroxytryptamine receptor 4 [5ht4r]) hold promise as a novel therapeutic approach to multiple brain disorders, including alzheimer and huntington disease. |
2014-06-23 |
2023-08-12 |
Not clear |
| Sebastiaan Engelborghs, Kristel Sleegers, Stefan Van der Mussele, Nathalie Le Bastard, Nathalie Brouwers, Christine Van Broeckhoven, Peter Paul De Dey. Brain-specific tryptophan hydroxylase, TPH2, and 5-HTTLPR are associated with frontal lobe symptoms in Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 35. issue 1. 2013-12-27. PMID:23334703. |
a prospective, longitudinal study was set up to investigate possible genetic associations of behavioral and psychological signs and symptoms of dementia (bpsd) in alzheimer's disease (ad) with two candidate genes in the serotonergic neurotransmitter pathway: serotonin transporter (slc6a4) and brain-specific tryptophan hydroxylase (tph2). |
2013-12-27 |
2023-08-12 |
Not clear |
| Xinhong Wang, Xiaohong Sun, Xiuqin Liu, Weiwei Ma, Wei Xie, Chao Wang, Decai Wan. [Determination of kinds of monoamine neurotransmitters in Alzheimer's blood plasma by high performance liquid chromatography]. Wei sheng yan jiu = Journal of hygiene research. vol 41. issue 6. 2013-12-19. PMID:23424877. |
a method detecting norepinephrine, epinephrine, dopamineand serotonin in alzheimer's blood plasma by high performance liquid chromatography was developed. |
2013-12-19 |
2023-08-12 |
Not clear |
| Amir A Sepehry, Philip E Lee, Ging Yuek R Hsiung, B Lynn Beattie, Claudia Jacov. Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. Drugs & aging. vol 29. issue 10. 2013-08-29. PMID:23079957. |
effect of selective serotonin reuptake inhibitors in alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. |
2013-08-29 |
2023-08-12 |
Not clear |
| T Hochstrasser, D Ehrlich, B Sperner-Unterweger, C Humpe. Antidepressants and anti-inflammatory drugs differentially reduce the release of NGF and BDNF from rat platelets. Pharmacopsychiatry. vol 46. issue 1. 2013-06-28. PMID:22699957. |
platelets store serotonin and brain-derived neurotrophic factor (bdnf) as well as amyloid precursor protein and nerve growth factor (ngf), thus platelets are of special interest in depression and alzheimer's disease, respectively. |
2013-06-28 |
2023-08-12 |
rat |
| Christoph Kraus, Andreas Hahn, Markus Savli, Georg S Kranz, Pia Baldinger, Anna Höflich, Christoph Spindelegger, Johanna Ungersboeck, Daniela Haeusler, Markus Mitterhauser, Christian Windischberger, Wolfgang Wadsak, Siegfried Kasper, Rupert Lanzenberge. Serotonin-1A receptor binding is positively associated with gray matter volume -- a multimodal neuroimaging study combining PET and structural MRI. NeuroImage. vol 63. issue 3. 2013-06-25. PMID:22836176. |
given the congruence of altered 5-ht(1a) receptor concentrations and gmv reduction in depression or alzheimer's disease as reported by numerous studies, these results might provide new insights towards understanding the mechanisms behind gmv alterations observed in these brain disorders. |
2013-06-25 |
2023-08-12 |
human |
| Agnes Fehér, Anna Juhász, Anna László, Magdolna Pákáski, János Kálmán, Zoltán Jank. Serotonin transporter and serotonin receptor 2A gene polymorphisms in Alzheimer's disease. Neuroscience letters. vol 534. 2013-06-18. PMID:23274704. |
serotonin transporter and serotonin receptor 2a gene polymorphisms in alzheimer's disease. |
2013-06-18 |
2023-08-12 |
Not clear |
| Gakuji Hashimoto, Mikako Sakurai, Andrew F Teich, Faisal Saeed, Fahad Aziz, Ottavio Aranci. 5-HT₄ receptor stimulation leads to soluble AβPPα production through MMP-9 upregulation. Journal of Alzheimer's disease : JAD. vol 32. issue 2. 2013-04-23. PMID:22810092. |
serotonin 4 (5-ht4) receptor signaling does not only have the physiological function of improving cognition, but might also be helpful in the therapy of alzheimer's disease (ad) through regulation of the production of soluble amyloid-β protein precursor alpha (saβppα). |
2013-04-23 |
2023-08-12 |
mouse |
| Hyung-Mun Yun, Hyewhon Rhi. The serotonin-6 receptor as a novel therapeutic target. Experimental neurobiology. vol 20. issue 4. 2013-03-14. PMID:22355260. |
preclinical studies provide support for the use of 5-ht(6)r ligands as promising medications to treat the cognitive dysfunction associated with alzheimer's disease, obesity, depression, and anxiety. |
2013-03-14 |
2023-08-12 |
Not clear |
| A Mogha, S R Guariglia, P R Debata, G Y Wen, P Banerje. Serotonin 1A receptor-mediated signaling through ERK and PKCα is essential for normal synaptogenesis in neonatal mouse hippocampus. Translational psychiatry. vol 2. 2013-03-04. PMID:22832728. |
finally, compared with the wild type, the 5-ht(1a)-r(-/-) mice harbor significantly less synapses in the hippocampus, but infusion of the pkc-stimulator and alzheimer drug bryostatin into the 5-ht(1a)-r(-/-) mice to bypass the non-existent 5-ht(1a)-r boosted psd95 expression and synaptogenesis. |
2013-03-04 |
2023-08-12 |
mouse |
| Alexandre V Ivachtchenko, Yan A Ivanenkov, Andrey V Skorenk. 5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds. Expert opinion on therapeutic patents. vol 22. issue 10. 2013-02-12. PMID:22957857. |
available biological data clearly indicate that 5-ht(6)r antagonists can be used as effective regulators in a variety of contexts, including memory formation, age-related cognitive impairments and memory deficits associated with conditions such as schizophrenia, parkinson's disease (pd) and alzheimer's disease (ad). |
2013-02-12 |
2023-08-12 |
Not clear |
| Saobo Le. Serotonergic modulation of Neural activities in the entorhinal cortex. International journal of physiology, pathophysiology and pharmacology. vol 4. issue 4. 2013-01-16. PMID:23320133. |
furthermore, the functions of serotonin in the ec may be implicated in parkinson's disease, alzheimer's disease and depression. |
2013-01-16 |
2023-08-12 |
Not clear |
| George Bartzoki. Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology. vol 62. issue 7. 2012-12-20. PMID:22306524. |
similarly, psychotropic treatments ranging from lithium and antipsychotics to serotonin reuptake inhibitors (ssris) and acetylcholinesterase inhibitors have been shown to be efficacious in a wide spectrum of psychiatric disorders ranging from autism, schizophrenia (sz), depression, and bipolar disorder (bd) to alzheimer's disease (ad). |
2012-12-20 |
2023-08-12 |
human |
| Alexandre V Ivachtchenko, Yan A Ivanenko. 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives. Expert opinion on therapeutic patents. vol 22. issue 8. 2012-11-27. PMID:22816965. |
available biological data clearly indicate that 5ht(6)r antagonists can be used as effective regulators in a variety of contexts, including memory formation, age-related cognitive impairments and memory deficits associated with conditions such as schizophrenia, parkinson's disease and alzheimer's disease. |
2012-11-27 |
2023-08-12 |
Not clear |